Study guide

10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

Key Takeaways Explain This Topic AI

Cardiorenal Syndrome (CRS) encompasses five subtypes of bidirectional heart-kidney crosstalk in which venous congestion (elevated central venous pressure and renal vein hypertension) drives worsening renal function in acute decompensated heart failure more than arterial forward underperfusion does; a creatinine rise of 0.3–0.5 mg/dL alongside genuine decongestion, falling CVP and brisk urine output is pseudo-worsening renal function from hemoconcentration rather than tubular injury, and loop diuretics should be continued rather than stopped.

Passive hepatic congestion ('nutmeg liver') results from chronic elevated right atrial pressure transmitted to hepatic veins, causing centrilobular necrosis, mildly elevated transaminases, hyperbilirubinemia and INR prolongation, whereas ischemic hepatitis ('shock liver') causes sudden transaminase elevations above 1,000 U/L within 12–48 hours of systemic hypoperfusion and falls rapidly once perfusion is restored.

The Berlin definition of ARDS deliberately removed the old wedge-pressure cutoff: respiratory failure must simply not be fully explained by cardiac failure or fluid overload, so a PAOP above 18 mmHg does not exclude ARDS and the two can coexist in the same cardiac patient.

PEEP acts as a cardiac drug — it reduces LV preload and afterload, which benefits cardiogenic pulmonary edema, but it raises pulmonary vascular resistance and can precipitate abrupt right ventricular decompensation in RV failure or pulmonary hypertension.

Periprocedural stroke is predominantly embolic and front-loaded: TAVR carries roughly a 2–3% 30-day stroke risk with about two-thirds of events in the first 48 hours, and cardioversion of AF lasting 48 hours or longer carries a 5–7% thromboembolic risk without adequate anticoagulation, falling below 1% with it.

Last updated: August 2026

Cardiorenal Syndrome (CRS): Subtypes & Pathophysiology

Cardiorenal Syndrome (CRS) represents a complex pathophysiological spectrum wherein acute or chronic dysfunction of the heart or kidneys induces acute or chronic dysfunction in the other organ. Heart-kidney crosstalk is driven by intricate hemodynamic, neurohormonal, and inflammatory feedback loops.

The 5 Subtypes of Cardiorenal Syndrome

Type 1 (Acute Cardiorenal Syndrome): Acute cardiac decompensation (e.g., acute MI, cardiogenic shock, acute decompensated heart failure) leads to Acute Kidney Injury (AKI) . Driven by abrupt drops in cardiac output and acute surges in central venous pressure.

Type 2 (Chronic Cardiorenal Syndrome): Chronic heart failure (e.g., chronic HFrEF or HFpEF) drives progressive, chronic kidney disease (CKD).

Type 3 (Acute Renocardiac Syndrome): Acute primary renal failure (e.g., acute glomerulonephritis, bilateral renal artery occlusion, acute tubular necrosis) causes acute cardiac dysfunction (e.g., acute pulmonary edema, hyperkalemic arrhythmias, uremic pericarditis).

Type 4 (Chronic Renocardiac Syndrome): Primary chronic kidney disease drives chronic cardiovascular disease (e.g., LV hypertrophy, accelerated coronary atherosclerosis, vascular calcification).

Type 5 (Secondary Cardiorenal Syndrome): Systemic disorders (e.g., severe sepsis, systemic lupus erythematosus, amyloidosis, diabetes mellitus) cause simultaneous, concurrent cardiac and renal dysfunction.

Hemodynamic Mechanisms: Venous Congestion vs. Arterial Underperfusion

Historically, kidney injury in heart failure was attributed almost exclusively to reduced forward cardiac output ( arterial forward underperfusion ). However, modern clinical research demonstrates that Venous Congestion —reflected by elevated Central Venous Pressure (CVP) and renal vein hypertension—is the primary driver of worsening renal function (WRF) in decompensated heart failure. P n e t = P glomerular capillary − [ P Bowman space + π glomerular capillary ] P_{net} = P_{\text{glomerular capillary}} - \left[ P_{\text{Bowman space}} + \pi_{\text{glomerular capillary}} \right] P n e t ​ = P glomerular capillary ​ − [ P Bowman space ​ + π glomerular capillary ​ ]

Venous congestion acts on this balance indirectly: rising renal vein and interstitial pressure raises Bowman-space pressure, while renal perfusion pressure itself is approximately MAP minus CVP — so a high CVP erodes the driving gradient from both ends.

Pathophysiology of Renal Congestion: High CVP transmits directly backward through the IVC into the renal veins, increasing intrarenal interstitial pressure. This causes renal parenchymal compression within the rigid renal capsule ("intrarenal compartment syndrome"), collapsing peritubular capillaries, dropping net glomerular filtration pressure, and precipitously decreasing GFR. Decompensated HF / Elevated RAP & CVP ---> Backward Transmission to Renal Veins

  • └──> Surging Renal Vein Pressure ---> Intrarenal Interstitial Edema (Compartment Syndrome)
  • └──> Reduced Net Glomerular Filtration Pressure ---> Acute GFR Collapse & Oligo-Anuria
  • Worsening Renal Function (WRF) During HF Decongestion

During aggressive diuretic therapy for acute decompensated heart failure, serum creatinine frequently rises. Distinguishing Pseudo-WRF from True Tubular Injury is critical:

Pseudo-WRF (Hemoconcentration): A transient rise in serum creatinine (0.3–0.5 mg/dL) occurring alongside effective decongestion (weight loss, declining CVP, net negative fluid balance). Reflects intraglomerular hemodynamic self-regulation without tubular injury; loop diuretics should NOT be discontinued.

True WRF (Acute Tubular Necrosis): Rising creatinine accompanied by persistent venous congestion, oliguria, electrolyte collapse, and elevated tubular injury biomarkers (e.g., NGAL, KIM-1). Requires immediate hemodynamic re-evaluation.

Loading diagram... Cardiorenal Syndrome Type 1 Pathophysiological Cascade

Cardiohepatic Syndrome: Congestive Hepatopathy Versus Ischemic Hepatitis

The liver is the second organ the failing heart injures, and it does so by two opposite mechanisms that produce opposite laboratory signatures. Confusing them pushes management in the wrong direction: one calls for decongestion , the other for restoring forward perfusion .

Congestive hepatopathy (historically "nutmeg liver," and cardiac cirrhosis once fibrosis is established) is a backward-failure problem. Chronically elevated right atrial pressure is transmitted through the hepatic veins into the sinusoids. Centrilobular (zone 3) hepatocytes sit farthest from the oxygenated portal and arterial inflow, so they congest, atrophy and eventually necrose first. Because the injury is slow and pressure-driven, transaminases stay modest while cholestatic and synthetic markers drift upward .

Ischemic hepatitis (also called shock liver or hypoxic hepatitis ) is a forward-failure problem. An abrupt fall in hepatic oxygen delivery — cardiogenic shock, a sustained hypotensive episode, a malignant arrhythmia — produces massive centrilobular necrosis within hours. Notably, frank hypotension is not always documented; in advanced right heart failure a congested liver is already on the edge of its oxygen supply, so a comparatively minor drop in cardiac output can tip it over.

  • Feature Congestive hepatopathy Ischemic hepatitis (shock liver)
  • Driving mechanism High RAP/CVP → hepatic venous congestion Abrupt fall in hepatic oxygen delivery
  • Time course Weeks to months, fluctuates with volume status 12–48 hours after the hemodynamic insult

AST / ALT Mild, usually under 2–3× the upper limit of normal Massive, commonly over 1,000 U/L (often 20–50× ULN)

Peak and resolution No discrete peak; tracks congestion Peaks at 24–72 hours, then falls rapidly once perfusion is restored

  • LDH Normal to mildly elevated Markedly elevated; a low ALT:LDH ratio favors ischemia over viral hepatitis
  • Bilirubin Elevated, often predominantly indirect Rises later and more modestly than the transaminases
  • INR Prolonged only in advanced disease Prolonged acutely; corrects as perfusion is restored

Bedside findings Hepatomegaly, hepatojugular reflux, ascites, pulsatile liver with tricuspid regurgitation The findings of the shock state itself

Treatment Decongest — diuresis, ultrafiltration, afterload reduction Restore cardiac output and MAP — inotropes, mechanical circulatory support, treat the cause

The two routinely coexist, and that combination is the classic exam vignette: a patient with advanced biventricular failure and a chronically high right atrial pressure who has a documented hypotensive event and then presents with transaminases in the thousands has ischemic hepatitis superimposed on chronic congestion , not a new primary liver disease. Chronic congestion alone does not produce transaminases in the thousands.

Nursing implications. Hepatic dysfunction changes drug handling in ways that matter on a cardiac unit. Congestion prolongs the INR independent of warfarin, so an unexpectedly high INR in a decompensated patient is not automatically an anticoagulation error. Hepatically cleared cardiac drugs — amiodarone, lidocaine, most statins, carvedilol — accumulate, and lidocaine toxicity in particular tracks hepatic blood flow rather than dose. Watch for hypoglycemia from failed gluconeogenesis, and monitor ammonia and mental status when the picture is severe. Serial trending, not a single value, tells you which process you are treating: transaminases that fall by roughly half within 72 hours confirm ischemic injury with restored perfusion.

Cardiogenic Pulmonary Edema Versus ARDS: Making the Call at the Bedside

Sections 3.2 and 9.2 teach each entity in full. What belongs here is the differential when both are plausible in the same patient , because that is how CMC tests it — a hypoxemic cardiac patient with bilateral infiltrates, where the wrong call sends you toward diuresis instead of lung protection.

The Berlin definition of acute respiratory distress syndrome requires all four of:

  • Onset within 1 week of a known clinical insult or new/worsening respiratory symptoms
  • Bilateral opacities on chest imaging, not fully explained by effusions, lobar collapse, or nodules
  • Respiratory failure not fully explained by cardiac failure or fluid overload
  • Impaired oxygenation graded by PaO₂/FiO₂ measured with PEEP or CPAP of at least 5 cmH₂O
  • ARDS severity PaO₂/FiO₂ ratio (with PEEP/CPAP ≥ 5 cmH₂O)
  • Mild 201–300 mmHg
  • Moderate 101–200 mmHg
  • Severe ≤ 100 mmHg

The single most misread point: the Berlin definition deliberately removed the older pulmonary artery occlusion pressure (PAOP) criterion of under 18 mmHg. A wedge of 14 mmHg does not by itself establish ARDS, and a wedge of 22 mmHg does not exclude it — the requirement is only that cardiac failure and fluid overload do not fully explain the picture. A patient can have both, and cardiac patients frequently do. Expect at least one item that supplies a wedge pressure specifically to see whether you still apply the retired rule.

  • Finding Favors cardiogenic edema Favors ARDS
  • PAOP / wedge Above 18 mmHg Usually at or below 18 mmHg, but not required

Echocardiography Reduced LVEF, elevated E/e′, significant valve lesion Normal LVEF with normal filling pressures

Radiographic pattern Perihilar "batwing," vascular redistribution, Kerley B lines, cardiomegaly, pleural effusions Peripheral, patchy, dependent ground-glass; normal heart size

  • BNP / NT-proBNP Markedly elevated Normal or only mildly elevated
  • Edema fluid : plasma protein ratio Under 0.65 (transudate) Over 0.75 (exudate)
  • Response to diuresis Rapid oxygenation improvement Little or no oxygenation benefit

PEEP behaves like a cardiac drug, and its effect depends on which ventricle is failing. Positive intrathoracic pressure lowers venous return, reducing preload , and lowers left ventricular transmural pressure, reducing afterload . In cardiogenic pulmonary edema with a failing left ventricle, both effects are therapeutic, which is why non-invasive ventilation improves oxygenation and work of breathing faster than diuresis alone. In right ventricular failure or pulmonary hypertension , the same pressure raises pulmonary vascular resistance and impedes RV ejection while cutting preload, and escalating PEEP can precipitate abrupt RV decompensation and hypotension. A patient whose blood pressure falls as PEEP rises is preload-dependent, RV-dependent, or both until proven otherwise — reassess volume status and RV function rather than reflexively adding vasopressor.

Neurologic Injury After Cardiac Procedures

Test-plan item II.D.1 (cerebrovascular accident) reaches the CMC exam mainly as a complication of the cardiac problem or of its treatment , which is a different lens from the primary stroke management taught in Section 10.6. The mechanism is almost always embolic: atheromatous or calcific debris liberated by catheters and devices, thrombus dislodged from a fibrillating left atrium, or air introduced through a sheath.

Setting Dominant mechanism Reported risk

TAVR Calcific and atheromatous debris released while crossing and deploying the valve About 2–3% stroke at 30 days in contemporary registries (STS/ACC TVT 2.3%; SwissTAVI 3.0%), with roughly two-thirds of events in the first 48 hours

Carotid artery stenting Plaque embolization during wiring and stent deployment Higher periprocedural stroke than carotid endarterectomy

Left-sided ablation for AF Char, thrombus on sheaths and catheters, or air embolism Under 1% with periprocedural anticoagulation and careful sheath management

Cardioversion of AF lasting ≥ 48 hours Dislodgement of pre-existing left atrial appendage thrombus, plus post-conversion atrial stunning 5–7% without adequate anticoagulation, falling to under 1% with therapeutic anticoagulation or a negative TEE

Left ventricular assist device Pump thrombosis, and hemorrhagic stroke driven by anticoagulation and acquired von Willebrand disease Both ischemic and hemorrhagic strokes occur; hypertension control is central to prevention

Two mechanisms deserve specific emphasis because they are frequently missed:

Atrial stunning after cardioversion. Mechanical atrial function does not return with the electrical rhythm. The appendage remains hypocontractile for days to weeks after sinus rhythm is restored, so thrombus can form and embolize post-procedure. That is why anticoagulation continues for at least 4 weeks after cardioversion regardless of how quickly the rhythm converted, and why a negative TEE permits earlier cardioversion but never shortens the post-procedure anticoagulation window.

Cholesterol (atheroembolic) syndrome. Catheter manipulation in a diseased aorta showers cholesterol crystals into multiple beds at once. Look for the triad of livedo reticularis or blue toes with intact distal pulses, a rising creatinine days after the procedure, and transient eosinophilia . It is easily mistaken for contrast-associated nephropathy, but the timing separates them: contrast injury peaks at 3–5 days and resolves, whereas atheroembolic injury appears later, progresses in a stepwise fashion, and involves the skin.

Nursing priority. For every post-procedure cardiac patient, a baseline neurologic assessment before the procedure is what makes the post-procedure exam interpretable. Perform structured, scheduled assessments — not a general "neuro intact" — in the first 24 to 48 hours, when the majority of periprocedural strokes present. Sedation and residual anesthesia mask deficits, so any new asymmetry, unexplained failure to wake, or focal finding is treated as a stroke alert until imaging says otherwise. Time is the variable you control: the interval from recognition to imaging determines whether reperfusion therapy is still an option, and recent arterial access changes the risk calculus for thrombolysis, making rapid neurology and interventional consultation essential.